Clinical Trials Directory

Trials / Completed

CompletedNCT01680926

Metabolic Activation With Almased for Type 2 Diabetes Patients

Protein-rich Meal Replacement Significantly Reduces Weight, HbA1c and Daily Insulin Requirement Long-term in Patients With Type 2 Diabetes Mellitus and >100 U Insulin Per Day

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
22 (actual)
Sponsor
West German Center of Diabetes and Health · Academic / Other
Sex
All
Age
35 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Overweight patients with type 2 diabetes are often being treated with an intensified insulin therapy. However, in many cases, even a high insulin dosage (\> 100 U per day) does not achieve satisfying metabolic control. A new therapy option is necessary that makes it possible to lower the daily insulin requirement and to improve metabolic control. The aim of this study was to investigate whether a protein-rich meal replacement is suitable to lower the daily insulin requirement and to reduce HbA1c and body weight.

Detailed description

The pilot study included patients with type 2 diabetes (n=22), that injected \>100 U insulin daily. During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced. Clinical parameters were determined at the beginning of the study, after 4, 8 and 12 weeks as well as after 1.5 years of follow-up. Wilcoxon signed rank test was used for the intention-to-treat analysis and Mann-Whitney test for subgroup analyses.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTAlmasedDuring the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.

Timeline

Start date
2009-07-01
Primary completion
2011-02-01
Completion
2011-10-01
First posted
2012-09-07
Last updated
2012-09-11

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01680926. Inclusion in this directory is not an endorsement.